Therapeutic targeting of miRNA-216b in cancer.

Apoptosis / genetics Biomarkers, Tumor / genetics Cell Proliferation / genetics Gene Expression Regulation, Neoplastic Genes, Tumor Suppressor Humans MicroRNAs / genetics Neoplasms / classification Prognosis Signal Transduction / genetics
Chemoresistance Therapy lncRNA microRNA

Journal

Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053

Informations de publication

Date de publication:
01 08 2020
Historique:
received: 16 03 2020
revised: 15 04 2020
accepted: 27 04 2020
pubmed: 11 5 2020
medline: 26 1 2021
entrez: 11 5 2020
Statut: ppublish

Résumé

MicroRNAs (miRNAs/or miR) are a type of small, non-coding RNAs that regulate gene expression by binding to 3'-UTRs of the target genes. miRNAs can serve as oncogenes or tumor suppressors, and have prognostic and therapeutic values that may be directly applicable in the clinic. miR-216b is located on chromosome 2p16.1. Accumulating evidence suggests that it acts as a tumor suppressor and its downregulation may play a significant role in cancer biology through the dysregulation of various oncogenes and signaling pathways related to cancer cell proliferation, cell cycle progression, migration, invasion, apoptosis, and chemoresistance. In this review, we discuss the aberrant expression of miR-216b in cancer and its role in tumor pathogenesis, which will offer novel insights into its clinical applications.

Identifiants

DOI: 10.1016/j.canlet.2020.04.020 PMID: 32387443
pubmed: 32387443
pii: S0304-3835(20)30214-7
doi: 10.1016/j.canlet.2020.04.020
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
MIRN216 microRNA, human 0
MicroRNAs 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

16-28

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no conflicts of interest to disclose.

Auteurs

Samir Jana (S)

Department of Medical Oncology, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA, 91010, USA.

Madhu Krishna (M)

Department of Medical Oncology, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA, 91010, USA.

Jyotsana Singhal (J)

Department of Medical Oncology, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA, 91010, USA.

David Horne (D)

Department of Medical Oncology, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA, 91010, USA.

Sanjay Awasthi (S)

Department of Internal Medicine, Division of Hematology & Oncology, Texas Tech University Health Sciences Center, Lubbock, TX, 79430, USA.

Ravi Salgia (R)

Department of Medical Oncology, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA, 91010, USA.

Sharad S Singhal (SS)

Department of Medical Oncology, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA, 91010, USA. Electronic address: ssinghal@coh.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › Therapeutic targeting of miRNA-216b in cancer.
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Therapeutic targeting of miRNA-216b in cancer.
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Therapeutic targeting of miRNA-216b in cancer.
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › Therapeutic targeting of miRNA-216b in cancer.
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Gènes suppresseurs de tumeur › Therapeutic targeting of miRNA-216b in cancer.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Therapeutic targeting of miRNA-216b in cancer.
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN non traduit › Petit ARN non traduit › microARN › Therapeutic targeting of miRNA-216b in cancer.
questionsmedicales.fr › Tumeurs › Therapeutic targeting of miRNA-216b in cancer.
questionsmedicales.fr › Diagnostic › Pronostic › Therapeutic targeting of miRNA-216b in cancer.
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Therapeutic targeting of miRNA-216b in cancer.